Abstracts Archive - Page 2175 of 2607 - ACR Meeting Abstracts

Abstract Number: 877 • 2014 ACR/ARHP Annual Meeting
Sildenafil Attenuates the Fibrotic Phenotype in Scleroderma Skin Fibroblasts
Tomoaki Higuchi¹, Yasushi Kawaguchi¹, Kae Takagi¹, Akiko Tochimoto¹, Yuko Ota², Yasuhiro Katsumata¹, Takahisa Gono¹, Masanori Hanaoka¹, Yuko Okamoto¹, Hidenaga Kawasumi¹ and Hisashi Yamanaka³, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²10-22 Kawada-Cha Shinjuku-Ku, Tokyo Women's Medical University, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose Systemic sclerosis (SSc) is a connective tissue disease characterized by inflammation, vasculopathy and fibrosis. Tissue fibrosis directly contributes to mortality or quality of life.…
Abstract Number: 876 • 2014 ACR/ARHP Annual Meeting
SAR100842, an Antagonist of Lysophaphatidic Acid Receptor 1, As a Potential Treatment for Patients with Systemic Sclerosis: Results from a Phase 2a Study
Dinesh Khanna¹, Christopher P. Denton², Alexandre Jagerschmidt³, Martine Jasson⁴, Oliver Distler⁵ and Yannick Allanore⁶, ¹University of Michigan Scleroderma Program, Ann Arbor, MI, ²Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School Royal Free Campus, London, United Kingdom, ³Tissue Protection and Repear Unit, Sanofi-Aventis, Chilly-Mazarin, France, ⁴Clinical Development, Sanofi-Aventis, Paris, France, ⁵Center of Experimental Rheumatology, Zurich University Hospital, Zurich, Switzerland, ⁶Department of Rheumatology, University Paris Descartes and Cochin Hospital, Paris, France
Background/Purpose Preclinical genetic and pharmacological studies suggest a role for Lysophosphatidic acid (LPA) involvement in three key processes of systemic sclerosis: fibrosis, microangiopathy and immunoinflammation.…
Abstract Number: 875 • 2014 ACR/ARHP Annual Meeting
Treatment-Related Outcomes in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: A Pooled Analysis of 12 Randomized Controlled Trials
Rennie L. Rhee¹, Nicole B. Gabler², Amy Praestgaard², Peter A. Merkel³ and Steven M. Kawut⁴, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴Pulmonary and Critical Care, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Recent studies have shown that therapies for pulmonary arterial hypertension (PAH) improve exercise capacity, but subgroup analyses suggest that these therapies may be less…
Abstract Number: 874 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of Subcutaneous Tocilizumab in Adults with Systemic Sclerosis: Week 24 Data from a Phase 2/3 Trial
Dinesh Khanna¹, Christopher P. Denton², Jacob M. van Laar³, Angelika Jahreis⁴, Sabrina Cheng⁴, Helen Spotswood⁵, Jeffrey Siegel⁴ and Daniel E. Furst on behalf of FaSScinate Clinical Trial in Patients With SS⁶, ¹University of Michigan Health System, Ann Arbor, MI, ²University College London Medical School, London, United Kingdom, ³University Medical Center Utrecht, Utrecht, Netherlands, ⁴Genentech, South San Francisco, CA, ⁵Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁶University of California, Los Angeles, CA
Background/Purpose: Systemic sclerosis (SSc) is a progressive, debilitating disease with limited treatment options. IL-6 has been implicated in disease pathogenesis.1,2 IL-6 receptor inhibition prevented and…
Abstract Number: 873 • 2014 ACR/ARHP Annual Meeting
The Second Messenger, Cyclic GMP-AMP Dinucleotide (cGAMP) and the Enzyme, Cyclic GMP-AMP Synthase (cGAS), Are Expressed in Systemic Lupus Erythematosus
Jie An¹, Joshua Woodward², Reynold Karr³, Thomas H. Teal⁴ and Keith B. Elkon¹, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Microbiology, University of Washington, Seattle, WA, ³Department of Medicine, University of Washington, Seattle, WA, ⁴Rheumatology, University of Washington, Seattle, WA
Background/Purpose: The type I IFNs (IFN-I), are strongly associated with Systemic Lupus Erythematosus (SLE). It is generally considered that IFN-I is induced by immune complexes…
Abstract Number: 872 • 2014 ACR/ARHP Annual Meeting
Interferon-α and Angiogenic Dysregulation in Pregnant Lupus Patients Destined for Preeclampsia
Danieli Andrade¹, Mimi Kim², Luz P. Blanco³, S. Ananth Karumanchi⁴, Gloria Koo⁵, Patricia M. Redecha⁶, Kyriakos A. Kirou¹, Angela M. Alvarez⁷, Melissa J. Mulla⁷, Mary K. Crow⁸, Vikki Abrahams⁷, Mariana J. Kaplan³ and Jane E. Salmon⁹, ¹Hospital for Special Surgery, New York, NY, ²Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, ³Systemic Autoimmunity Branch, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁵Autoimmunity & Inflammation, Hospital for Special Surgery, New York, NY, ⁶Rheumatology Research, Hospital for Special Surgery, New York, NY, ⁷Yale School of Medicine, New Haven, CT, ⁸Department of Medicine, Hospital for Special Surgery, New York, NY, ⁹Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Pregnant patients with SLE are at increased risk of placental insufficiency and preeclampsia, disorders associated with angiogenic factor imbalance. IFN-α, a critical element in…
Abstract Number: 871 • 2014 ACR/ARHP Annual Meeting
Antimalarials Regulate TLR7/8 Mediated Macrophage Activation Via Epigenetic Modification at the TNFα Promoter
Androo J. Markham^1,2, Mark Halushka³, Cristiana Guiducci⁴, Robert M. Clancy⁵ and Jill P. Buyon⁵, ¹Medicine, New York University School of Medicine, New York, NY, ²Medicine, Equal contributing author, New York, NY, ³Division of Cardiovascular Pathology, John Hopkins Pathology, Baltimore, MD, ⁴Discovery Department, Dynavax Technologies, Berkeley, CA, ⁵Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Maternal anti-SSA autoantibodies contribute to the pathogenesis of congenital heart block by the formation of immune complexes (IC) comprised of Ro and ssRNA (hY3)…
Abstract Number: 870 • 2014 ACR/ARHP Annual Meeting
IRF1 Influences on Histone H4 Acetylation in Systemic Lupus Erythematosus
Yiu Tak Leung¹, Lihua Shi², Kelly Maurer², Li Song², Zhe Zhang³, Michelle Petri⁴ and Kathleen E. Sullivan², ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Immunology ARC 1216, The Children's Hospital of Philadelphia, Philadelphia, PA, ³Bioinformatics, Bioinformatics, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is the classical systemic autoimmune disease. Epigenetic processes, such as posttranslational histone modifications, can regulate gene expression without altering the…
Abstract Number: 869 • 2014 ACR/ARHP Annual Meeting
UBE2L3 genotype Influences Plasma Cell Proliferation in Systemic Lupus Erythematosus By Regulation of NF-κB By the Linear Ubiquitination Assembly Complex
Myles J. Lewis¹, Simon Vyse¹, Adrian M. Shields², Sebastian Boeltz², Patrick Gordon³, Timothy D. Spector⁴, Paul J. Lehner⁵, Henning Walczak⁶ and Timothy J. Vyse², ¹Experimental Medicine & Rheumatology, Queen Mary University of London, London, United Kingdom, ²Medical & Molecular Genetics, King's College London, London, United Kingdom, ³Department of Rheumatology, King's College London, London, United Kingdom, ⁴Department of Twin Research, King's College London, London, United Kingdom, ⁵Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom, ⁶Centre for Cell Death, Cancer and Inflammation, University College London, London, United Kingdom
Background/Purpose: Genome-wide association studies have identified a strong association between a single risk haplotype of the UBE2L3gene and Systemic Lupus Erythematosus (SLE), as well as…
Abstract Number: 867 • 2014 ACR/ARHP Annual Meeting
Specific SLE Disease Manifestations in the Six Months Prior to Conception Predict Similar Manifestations during Pregnancy
Sara K. Tedeschi¹, Hongshu Guan¹, Alexander Fine¹, Bonnie L. Bermas² and Karen H. Costenbader², ¹Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Active SLE, in particular lupus nephritis, during the six months prior to conception is associated with disease flare during pregnancy. Previous studies, however, have…
Abstract Number: 868 • 2014 ACR/ARHP Annual Meeting
Protein Phosphatase 5 (PP5) Regulates Methylation Sensitive Gene Expression in CD4+ T Cells
Dipak R. Patel, Gabriela Gorelik and Bruce C. Richardson, Internal Medicine, University of Michigan, Ann Arbor, MI
Background/Purpose: CD4+CD28- T cells are enriched in chronic inflammatory diseases like rheumatoid arthritis (RA) and lupus. They are cytotoxic and resistant to apoptosis. Compared to…
Abstract Number: 865 • 2014 ACR/ARHP Annual Meeting
Cardiovascular Events Prior to or Early after Diagnosis of SLE
Murray B. Urowitz¹, Dafna D. Gladman¹, Nicole Anderson², Dominique Ibanez³ and Systemic Lupus International Collaborating Clinics (SLICC)⁴, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Toronto Western Hospital, Division of Rheumatology, University of Toronto, Toronto Western Hospital (Coordinating Center), Toronto, ON, Canada
Background/Purpose: A large multicenter multinational inception cohort was established to study risk factors for atherosclerosis (AS) in SLE. Previous studies have shown a history of…
Abstract Number: 866 • 2014 ACR/ARHP Annual Meeting
Heart Rate Variability: An Inflammatory Biomarker in Systemic Lupus Erythematosus
Aikaterini Thanou¹, Stavros Stavrakis², John Dyer², Stan Kamp³, Melissa E. Munroe⁴, David Albert⁵, Judith A. James⁶ and Joan T. Merrill³, ¹Arthritis and Clinical Immmunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Heart Rhythm Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵AliveCor, Inc., San Francisco, CA, ⁶Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Heart rate variability (HRV) is a marker of vagus nerve activity and can be easily obtained with minimal technical expertise in the outpatient setting,…
Abstract Number: 864 • 2014 ACR/ARHP Annual Meeting
Association of Coronary Artery Calcification with Brown and White Pericardial Adipose Tissue in SLE
Kelly J. Shields, Medicine, Lupus Center of Excellence / Allegheny Health Network, Pittsburgh, PA
Background/Purpose Women with systemic lupus erythematosus (SLE) have an increased risk of cardiovascular disease (CVD). We have shown that clinically CVD-free women with SLE have…
Abstract Number: 863 • 2014 ACR/ARHP Annual Meeting
Metabolic Syndrome in Young Premenopausal Female Lupus Patients Is Mainly Influenced By Therapies
Luciana Muniz¹, Rosa M.R. Pereira², Thiago Silva³, Eloisa Bonfá⁴ and Eduardo Ferreira Borba¹, ¹Rheumatology Division, University of São Paulo, São Paulo, Brazil, ²Rheumatology, University of São Paulo, São Paulo, Brazil, ³Rheumatology Division, University of Sao Paulo, São Paulo, Brazil, ⁴Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: A high prevalence of metabolic syndrome (MetS) has been observed in Systemic Lupus Erythematosus (SLE) patients, but there are scarce data about the main…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].